SBIR Phase I: Rapid repurposing and translation of COVID-19 therapeutics using a AI-based biosimulation platform: application to ACE2 and Ca2+ multi-target therapies (COVID-19)
National Science Foundation
· United States · $2.56M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.